Cell Death and Disease: Simultaneous expression of SMYD3 and PKM2 can serve as a new biomarker for diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoma, accounting for about one-third of non-Hodgkin
lymphoma cases worldwide.

Although the addition of rituximab to cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (RCHOP) chemotherapy regimens improves survival in patients with DLBCL, nearly 40% of patients are resistant to this chemotherapy regimen, resulting in a poor prognosis
.

Image source: https://doi.

Recently, researchers from the Shanghai Cancer Center of Fudan University published an article titled "SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription" in the journal Cell Death and Disease.

Histone methyltransferase (HMTs) gene abnormalities are common in diffuse large B-cell lymphoma (DLBCL) and are associated
with its progression.

The upregulation of SMYD3 protein expression was positively correlated
with poor prognosis and poor chemotherapy response in patients with DLBCL.

Mechanism summary diagram

Image source: https://doi.

In summary, this study found a new aerobic yeast positive regulator SMYD3, which is significantly overexpressed in DLBCL tissues and positively correlated
with Ann Arbor stage, serum LDH level and prognosis and adverse chemotherapy response in patients with DLBCL.

These observations elucidate the role of the SMYD3/H3K4me3/PKM2 axis in DLBCL, suggesting that SMYD3 may be a new prognostic biomarker and/or therapeutic target for DLBCL
.

References

Tian Tian et al.